Open Label Extension Study to Protocol C2/13/DR-6MP-02
NCT01433432
·
clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class
Stopped
Sponsor withdrew support for study due to reorganization and project prioritization
Conditions
Crohn's Disease
Interventions
DRUG:
80 mg DR-6MP
Sponsor
Teva GTC